Comparison of risk of hyperkalemia between SGLT2 inhibitors and DPP4-inhibitors in patients with type 2 diabetes

Abstract Funding Acknowledgements Type of funding sources: None. Background Hyperkalemia is a common complication and increases the risk cardiac arrhythmias mortality in patients with type 2 diabetes (T2DM), especially those diabetic nephropathy. We investigated hyperkalemia initiated on SGLT2 inhibitors versus DPP-4 among T2DM. Methods This study included T2DM who or between January 01, 2015 December 31, 2019 from territory-wide clinical registry Hong Kong (Clinical Data Analysis Reporting System [CDARS]). A multivariable cox proportional hazards analysis, adjusting for key confounders, was used to compare central laboratory-determined (serum potassium ≥6.0mmol/L) hypokalemia <3.5mmol/L), respectively, inhibitors. Results 10193 new users were matched 17305 During 2-year follow-up, there 104 events (incident rate [IR] = 5.17 per 1000 person-years) 306 (IR 9.09 inhibitors, which associated lower incident (Adjusted HR: 0.66 [95%CI 0.53-0.83], p<0.001), compared The similar 0.91 0.81-1.03], P=0.13). Conclusion reduced hyperkalemia, but without increasing